Updated April 21, 2020

FAQs: Provision of methadone and buprenorphine for the treatment of 

Opioid Use Disorder in the COVID-19 emergency

1. Can a practitioner working in an Opioid Treatment Program (OTP), admit a new patient with opioid use disorder 

(OUD) to an OTP using telehealth (including use of telephone, if needed)?

Answer: Federal law requires a complete physical evaluation before admission to an OTP. 

Under 42 C.F.R. § 8.12(f)(2):

(f) Required services— . . . 

(2) Initial medical examination services. OTPs shall require each patient to undergo a complete, 

fully documented physical evaluation by a program physician or a primary care physician, or an 

authorized healthcare professional under the supervision of a program physician, before 

admission to the OTP. The full medical examination, including the results of serology and other 

tests, must be completed within 14 days following admission.

However, under 42 C.F.R. § 8.11(h), SAMHSA has the authority to grant exemptions to OTPs from certain 

requirements of the OTP regulations. 

With respect to new patients treated with buprenorphine, SAMHSA has made the decision to pre-emptively 

exercise its authority to exempt OTPs from the requirement to perform an in-person physical evaluation (under 

42 C.F.R. § 8.12(f)(2)) for any patient who will be treated by the OTP with buprenorphine if a program physician, 

primary care physician, or an authorized healthcare professional under the supervision of a program physician, 

determines that an adequate evaluation of the patient can be accomplished via telehealth. This exemption will 

continue for the period of the national emergency declared in response to the COVID-19 pandemic, and applies 

exclusively to OTP patients treated with buprenorphine. This exemption does not apply to new OTP patients 

treated with methadone. In addition, treatment of OTP buprenorphine patients must be done in accordance 

with SAMHSA’s OTP guidance issued on March 16, 2020. See https://www.samhsa.gov/sites/default/files/otpguidance-20200316.pdf. The OTP provider caring for the buprenorphine patient under these circumstances 

must be a licensed healthcare practitioner who can, in his or her scope of practice prescribe or dispense 

medications and have a current, valid DEA registration permitting prescribing or dispensing of medications in the 

appropriate Controlled Substances Schedule.

For new OTP patients that are treated with methadone, the requirements of an in-person medical evaluation 

will remain in force. SAMHSA has made this determination on the basis that eliminating the in-person physical 

examination requirement for new methadone patients could present significant issues for a patient with OUD. 

Patients with OUD starting methadone are not permitted to receive escalating doses for induction as take home 

medication. This means that a person starting methadone for OUD would get a maximum dose of 30 mg/d and 

may be on this dose, which for most people with OUD would be a low dose that will potentially be inadequate, 

for extended periods (up to 14 days if the clinic is using a blanket exception during the current medical 

emergency). The methadone dose could only be increased by a small amount (e.g., 5 mg/d) meaning that the 

person would be on what are considered to be subtherapeutic doses of methadone to treat OUD for an 

extended period. An initial in-person physical evaluation is needed in order for OTP providers to address such 

risks in each newly admitted methadone patient. 
2. Can a practitioner working in an Opioid Treatment Program continue to treat an existing OTP patient using 

methadone via telehealth (including use of telephone, if needed)?

Answer: Yes, a practitioner may continue treating an existing patient of the OTP with methadone via telehealth 

and in accordance with SAMHSA’s OTP guidance issued on March 16, 2020, assuming applicable standards of 

care are met. See https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf. The OTP provider 

caring for the methadone patient under these circumstances must be a licensed healthcare practitioner who 

can, in his or her scope of practice prescribe or dispense medications and have a current, valid DEA registration 

permitting prescribing or dispensing of medications in the appropriate Controlled Substances Schedule.

3. Can a practitioner working in an Opioid Treatment Program, continue to treat an existing OTP patient using

buprenorphine via telehealth (including use of telephone, if needed)?

Answer: Yes, a practitioner may continue treating an existing patient of the OTP with buprenorphine via 

telehealth assuming applicable standards of care are met, and the patient’s buprenorphine treatment is in 

accordance with SAMHSA’s OTP guidance issued on March 16, 2020. See 

https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf. The OTP provider caring for the 

methadone patient under these circumstances must be a licensed healthcare practitioner who can, in his or her

scope of practice prescribe or dispense medications and have a current, valid DEA registration permitting 

prescribing or dispensing of medications in the appropriate Controlled Substances Schedule.

4. Can a practitioner with a DATA 2000 waiver, and working outside the context of an OTP, treat new and existing

patients with buprenorphine via telehealth (including use of telephone, if needed)?

Answer: Yes, if a practitioner, has a DATA 2000 waiver, the practitioner may prescribe buprenorphine under the 

practitioner’s DATA 2000 waiver while complying with all applicable standards of care. In such a case, the 

patient will count against the practitioner’s patient limit and must treat the patient in accordance with any rules 

that apply to practicing with a waiver under 21 U.S.C. § 823(g)(2), and 42 C.F.R. Part 8, as applicable.

5. Can an OTP dispense medication (either methadone or buprenorphine products) based on telehealth (including 

telephone, if needed) evaluation?

Answer: Yes. Under the current national health emergency, OTPs can provide medication under blanket 

exception: up to 14 doses for clinically less stable patients and 28 doses for clinically stable patients (clinical 

stability and ability to safely manage medication must be determined by the clinical team and documented in 

the patient’s medical record).See https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf.

6. Can OTP mid-level practitioners continue to dispense and administer MAT medications at an OTP in the event 

that their supervising provider can no longer provide supervision regarding the administration or dispensing of 

MAT medications? 

Answer: OTP regulations under 42 C.F.R. § 8.12(h)(1) provide that: 

OTPs must ensure that opioid agonist treatment medications are administered or dispensed only by a 

practitioner licensed under the appropriate State law and registered under the appropriate State and 

Federal laws to administer or dispense opioid drugs, or by an agent of such a practitioner, supervised by 

and under the order of the licensed practitioner. This agent is required to be a pharmacist, registered 

nurse, or licensed practical nurse, or any other healthcare professional authorized by Federal and State 

law to administer or dispense opioid drugs.

Therefore, a mid-level practitioner can administer and dispense MAT medication within an OTP, absent the 

direct supervision of an OTP physician, if the mid-level practitioner is “licensed under the appropriate State law 

and registered under the appropriate State and Federal laws to administer or dispense opioid drugs.” Please 
note, however, that this flexibility does not negate the OTP medical director’s obligation to “assume 

responsibility for administering all medical services performed by the OTP.” See 42 C.F.R. § 8.12(b). 

7. Is an OTP required to send an exemption request when any provider other than the medical director assumes 

responsibility for performing a medical director’s functions under 42 CFR § 8.12(i)(2) regarding unsupervised 

take home medications?

Answer: Yes. 42 CFR § 8.12(i)(2) states that, “[t]reatment program decisions on dispensing opioid treatment 

medications to patients for unsupervised use beyond that set forth in [42 CFR § 8.12(i)(1)], shall be determined 

by the medical director.” Therefore, OTPs must request an exemption when any practitioner other than the 

medical director assumes responsibility for making decisions regarding unsupervised take home medication 

orders or dosing changes. Medical directors may assign tasks related to these functions to an appropriately 

trained and licensed practitioner, including mid-level providers, but such tasks must be performed under the 

supervision of the medical director. The medical director must remain responsible for all medical services 

delivered at the corresponding OTP.

8. Does an OTP need to submit an exemption request when an OTP wishes to change its medical director, 

assuming the new medical director is an appropriately licensed physician? 

Answer: No, OTPs do not need to submit an exemption request when simply changing medical directors. 

However, the OTP does need to notify SAMHSA when a medical director change has occurred pursuant to 42 

C.F.R. § 8.11(f)(5). 

9. Will SAMHSA approve exemptions for mid-level providers to be designated as medical directors?

Answer: No. Under 42 CFR § 8.2, a medical director must be a physician, and therefore, mid-level providers 

cannot be a medical director of an OTP. 

10. May an OTP request an exemption to allow mid-level practitioners to perform functions that are required to be 

performed by an OTP physician or the medical director (under 42 C.F.R. § 8.12) in the event the medical director 

or physician cannot perform the regulatory functions?

Answer: Yes, an OTP may request an exemption from the requirements of 42 CFR § 8.12 in order to have midlevel providers perform functions related to admitting patients, ordering unsupervised take home medication, or 

changing medication doses during the COVID-19 emergency if consistent with applicable state law and the midlevel provider’s scope of licensure. 

11. Should OTP’s specifically identify by name the mid-level practitioner to take on these functions?

Answer: No, The names of the individual practitioners are not required for these exemption requests. 

12. What OTP medical director or program physician functions require an exemption in order to be independently 

performed by a mid-level practitioner? 

Answer: Mid-level providers acting under the direct supervision of a medical director or program physician do 

not require an exemption to perform functions under 42 C.F.R. § 8.12. An exemption from SAMHSA is required 

for mid-level practitioners to independently, i.e., without the supervision of the medical director or a program 

physician, perform the following medical director or physician functions in an OTP based on the Federal opioid 

treatment standards under 42 C.F.R. § 8.12:

§ 8.12(b) Administrative and organizational structure.

• Assuming responsibility for administering all medical services performed by an OTP (a function of the 

medical director). 
• Assuming responsibility for ensuring that the OTP is in compliance with all applicable Federal, State, and 

local laws and regulations (a function of the medical director).

§ 8.12(e) Patient admission criteria -

• Ensuring that each patient voluntarily chooses maintenance treatment and that all relevant facts concerning 

the use of the opioid drug are clearly and adequately explained to the patient, and that 

each patient provides informed written consent to treatment (a function of a program physician).

• Waiving, when clinically appropriate, the requirement of a 1-year history of addiction under 42 C.F.R. § 

8.12(e)(1), for patients released from penal institutions (within 6 months after release), for 

pregnant patients, and for previously treated patients (up to 2 years after discharge). (A function of a 

program physician.)

• Certifying pregnancy for purposes of the above bullet point (a function of a program physician.)

• Assessing patients with two or more unsuccessful detoxification episodes within a 12-month period for 

other forms of treatment (a function of a program physician). 

§ 8.12(h) Medication administration, dispensing, and use.

• Documenting in a patient's record that 40 milligrams did not suppress opioid abstinence symptoms 

when providing an initial dose of methadone in excess of 30 milligrams or 40 milligrams in the first day 

(a function of a program physician). 

• Making dosing and administration decisions (a function of a program physician that is “familiar with the 

most up-to-date product labeling.”)

§ 8.12 (i) Unsupervised or “take-home” use.

• Making OTP decisions on dispensing opioid treatment medications to patients for unsupervised use 

beyond that set forth in 42 C.F.R. § 8.12(i)(1) (a function of the medical director). 

• Considering the take-home criteria listed in 42 C.F.R. 8.12(i)(2) when determining which patients may be 

permitted unsupervised use (a function of the medical director).

13. If the OTP has received an exemption from SAMHSA for a mid-level practitioner to perform designated functions 

of the medical director or program physician and subsequently that mid-level practitioner becomes unavailable, 

does the OTP need to submit another exemption request identifying the new midlevel by name? 

Answer: No, if the mid-level exemption request has been approved, but the mid-level practitioner is no longer 

able to perform the designated duties, for instance due to illness, the OTP is not required to submit another 

request identifying the new mid-level practitioner during the exemption timeframe. 

Practitioners may request an OTP Extranet account at http://otp-extranet.samhsa.gov/request/